60
Participants
Start Date
August 31, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
December 31, 2014
Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
Sofia
Sofia
Plovdiv
Varna
Marseille
Berlin
Hamburg
Toulouse
Istanbul
Istanbul
Bonn
Samsun
Odesa
Paris
Donetsk
Uzhhorod
Créteil
Moscow
Moscow
Moscow
Saint Petersburg
Saratov
Leipzig
Krakow
Lodz
Lublin
Warsaw
Warsaw
Wroclaw
Istanbul
Kiev
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY